ON
← Back to feed
Warning issued to millions on atorvastatin for high cholesterol
United Kingdom🏛️ PoliticsCenter11 days ago

Warning issued to millions on atorvastatin for high cholesterol

An article published in The Daily Mirror warns about potential side effects associated with atorvastatin, a widely prescribed cholesterol-lowering drug in the UK. It highlights concerns regarding drug interactions and rare but serious conditions like myopathy and rhabdomyolysis. The piece references data from the National Institute for Health and Care Excellence (NICE), noting that over 5.3 million people in England are prescribed statins. A pharmaceutical expert, Dipa Kamdar from Kingston University, explains that while statins can cause common side effects such as headaches and digestive issues, the overall benefits, particularly in reducing heart attack risk, outweigh these concerns. She emphasizes the importance of monitoring for adverse reactions and consulting healthcare professionals. The article also discusses how certain medications can interact with statins, increasing the risk of muscle-related complications.

A warning has been issued regarding the use of atorvastatin, a widely prescribed cholesterol-lowering drug, following concerns about its interaction with other medications and potential side effects. Millions of people in the United Kingdom rely on statins to manage high cholesterol, but recent discussions highlight the importance of understanding both the benefits and risks associated with these medications. An estimated 7 to 8 million adults in the UK take prescribed statins, according to data from the National Institute for Health and Care Excellence (NICE). Over 5.3 million individuals in England alone are prescribed these drugs, which are among the most commonly dispensed by the NHS. A pharmacist and senior lecturer in pharmacy practice, Dipa Kamdar from Kingston University, emphasized that while statins offer substantial health benefits, they come with potential side effects that require careful monitoring. Kamdar outlined common side effects of statins, including headaches, digestive issues, and dizziness. She also mentioned more serious but rare complications such as liver inflammation and muscle problems, specifically noting a condition called myopathy, characterized by muscle pain or weakness accompanied by elevated levels of creatine kinase, an enzyme released during muscle damage. In extreme cases, a severe form of muscle breakdown known as rhabdomyolysis can occur, although this is exceptionally rare, affecting only a few individuals per million users. The pharmacist highlighted that the risk of adverse effects increases when statins are combined with other medications that interfere with their metabolism. These interactions primarily involve drugs that inhibit the CYP3A4 enzyme in the liver, which plays a crucial role in breaking down statins. Medications such as antifungals like ketoconazole, certain antibiotics like erythromycin, immunosuppressants such as ciclosporin, and specific heart drugs including amiodarone and diltiazem can elevate the risk of muscle-related side effects. Grapefruit juice also poses a similar risk due to its content of furanocoumarins, which inhibit CYP3A4 enzymes in the gut, thereby increasing the amount of statin absorbed into the bloodstream. Not all statins are equally affected by these interactions, suggesting that switching to a different type of statin might mitigate this risk. Despite these considerations, Kamdar stressed that the benefits of statins generally outweigh their risks, especially for individuals with pre-existing conditions such as diabetes or prediabetes. While statins can lead to a slight increase in blood glucose levels, the reduction in heart attack risk is significant enough to justify their use. Most side effects are reversible upon discontinuation of the medication, unlike the potentially irreversible damage caused by heart attacks or strokes. Recent studies have sparked debate about the necessity of statins for certain demographics, particularly older adults. Research conducted by French scientists indicated that millions of Britons over 75 who take statins might not necessarily need them, as stopping the medication does not significantly increase their risk of death or major cardiovascular events. This study, involving 1,160 participants with an average age of 80, found minimal statistical differences in outcomes between those who discontinued statins and those who continued taking them. However, experts caution against interpreting these results as a universal recommendation to discontinue statin use. Professor Robert Storey from the University of Sheffield emphasized the need for further research involving larger populations before making broad recommendations. He pointed out that the study’s limitations, including the relatively small sample size and the participants’ generally healthy lifestyles, might influence the interpretation of the findings. While the study noted a rise in LDL cholesterol levels among those who stopped taking statins, it also underscored the importance of maintaining healthy cholesterol levels through lifestyle modifications. Experts continue to advocate for a combination of dietary changes, regular physical activity, and weight management as essential components of managing cardiovascular risk. Reducing saturated fat intake and replacing it with unsaturated fats found in foods like olive oil, nuts, and seeds can contribute significantly to lowering LDL cholesterol levels and improving overall heart health.

Go to the primary sources (1)

The official sources this coverage is built on. Read them directly to bypass framing.

2 reports

Daily Mirror logoDaily MirrorIndependentCenterFactual 85Objective 7011 days ago
Warning issued to millions on atorvastatin for high cholesterol

An article published in The Daily Mirror warns about potential side effects associated with atorvastatin, a widely prescribed cholesterol-lowering drug in the UK. It highlights concerns regarding drug interactions and rare but serious conditions like myopathy and rhabdomyolysis. The piece references data from the National Institute for Health and Care Excellence (NICE), noting that over 5.3 million people in England are prescribed statins. A pharmaceutical expert, Dipa Kamdar from Kingston University, explains that while statins can cause common side effects such as headaches and digestive issues, the overall benefits, particularly in reducing heart attack risk, outweigh these concerns. She emphasizes the importance of monitoring for adverse reactions and consulting healthcare professionals. The article also discusses how certain medications can interact with statins, increasing the risk of muscle-related complications.

Bias read (Center): The article presents information based on medical research and expert opinion without overtly favoring any political ideology. While it raises concerns about statin side effects, it also emphasizes the overall benefits of the medication, balancing both perspectives. The framing remains neutral, with

Why factuality (85): The article accurately describes common and serious side effects of atorvastatin, including myopathy and rhabdomyolysis, as outlined in the primary source. It also mentions drug interactions and the importance of consulting a GP, which aligns with the source material. The information about NICE data

Why objectivity (70): The article maintains a generally neutral tone but uses phrases like 'serious side effects' and 'people need to be wary' which could be seen as slightly alarmist. While it acknowledges that benefits outweigh risks, the focus on potential dangers may create a skewed perception. The article does not p

Daily Mail logoDaily MailIndependentCenterFactual 75Objective 6512 days ago
More than a million adults taking statins might not need them, study suggests - but experts urge caution

A study led by Bordeaux University Hospital suggests that millions of British adults over 75 taking statins may be able to discontinue the medication without increasing their risk of death. The research followed 1,160 French adults aged 80 on average, comparing outcomes for those who stopped versus continued statin therapy. After three years, there were no statistically significant differences in mortality rates or major cardiovascular events between the two groups. However, those who stopped experienced a 50% increase in LDL cholesterol levels, which could contribute to arterial narrowing. While the study concludes that stopping statins is 'noninferior' to continuing them, experts caution against making individual decisions without medical advice.

Bias read (Center): The article presents a scientific study without overt ideological framing. It reports findings neutrally, highlighting both the study's conclusions and expert cautions. There is no clear leaning toward either side of the political spectrum, and the emphasis is on medical evidence rather than policy,

Why factuality (75): The article reports on a study suggesting that older adults may safely stop statins without increased risk of death, aligning with the primary source document's discussion of statin effectiveness and side effects. However, it omits details about the broader context of statin use, including their rol

Why objectivity (65): The tone leans slightly towards sensationalism by highlighting 'millions' and 'warning,' which may exaggerate the significance of the findings. The article presents the study results without sufficient balance, failing to mention that the study was limited to older adults and did not address younger

How each side covered it

The same event, grouped by the political lean of the outlets covering it.

How each side covered it

Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.

Become a Supporter

Covered around the world

The same event as reported in other countries.

Covered around the world

Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.

Become a Supporter

Claims check

Key factual claims, and how many sources assert vs dispute each.

Claims check

Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.

Become a Supporter

Keep the news honest.

ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €4/month.

Become a Supporter

Related stories